Osteoarthritis (OA) is characterized by deterioration of the joints and associated with considerable pain and disability. OA is a chronic disease that requires intervention with both non-pharmacological and pharmacological treatment modalities and, inevitably, disease progression may necessitate successive treatments throughout the course of the disease. There is increasing data on the shortfalls of current pharmacological treatment of OA, and safety concerns associated with analgesic therapy use in OA arising from increasing evidence of gastrointestinal, cardiovascular, hepatic and renal adverse events with paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Consequently, symptomatic slow-acting drugs for OA (SYSADOAs) may now be considered as a first-line treatment for knee OA, with a particular emphasis placed on the outstanding benefit: risk ratio of pharmaceutical-grade glucosamine and chondroitin sulfate formulations. In this short communication we review recent publications concerned with the safety of paracetamol, NSAIDs and SYSADOAs. Greater understanding of the benefits and limitations of current medications will lead to better disease management in OA. Furthermore, adherence to guideline recommendations across Europe and internationally, such as those from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), will promote evidence-based medicine and patient-centric care, ultimately leading to greater physician and patient satisfaction.

2 Department of Orthopaedic and Trauma Surgery Faculty of Medicine in Bratislava Comenius University University Hospital Bratislava Bratislava Slovakia

Chair for Biomarkers of Chronic Diseases Biochemistry Department College of Science King Saud University Riyadh Kingdom of Saudi Arabia

Clinic of Rheumatology MMA Medical Faculty University of Defence Military Medical Academy Belgrade Serbia

Clinical Pharmacology and Pharmacovigilance Operative Unit Department of Health Sciences MaterDomini Hospital Catanzaro University of Magna Graecia Catanzaro Catanzaro Italy

Department of Internal Medicine Clinic of Endocrinology Medical University Sofia University Hospital Alexandrovska Sofia Bulgaria

Department of Internal Medicine Rheumatology and Clinical Immunology Medical University of Silesia Katowice Poland

Department of Orthopedics General Hospital Jesenice Jesenice Slovenia

Department of Pediatric Rheumatology Immunology and Metabolic Bone Diseases Medical University of Bialystok Bialystok Poland

Department of Sports Medicine Faculty of Medicine University of Debrecen Debrecen Hungary

Division of Public Health Epidemiology and Health Economics University of Liège CHU Sart Tilman B23 4000 Liege Belgium

Institute of Rheumatology University of Belgrade Medical School Resavska 69 Belgrade Serbia

MRC Lifecourse Epidemiology Unit Southampton General Hospital University of Southampton Southampton UK

National Institute for Health Research Musculoskeletal Biomedical Research Unit University of Oxford Oxford UK

Orthopedic and Trauma Department Medical Veteran's Memorial Hospital University of Lodz Lodz Poland

Osteocentrum Mediekos Ltd Orthopedics Ortopedie Hradiště Ltd Uherské Hradiště Czech Republic

Rheumatology Clinic Medical Faculty University Hospital St Iv Rilski Medical University Sofia Bulgaria

Ultramedica Vošnjakova 1 Ljubljana Slovenia

WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging Liege Belgium

Rheumatol Int. 2019 Sep;39(9):1661-1662. doi: 10.1007/s00296-019-04347-z. PubMed

Zobrazit více v PubMed

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946 PubMed

Osteoarthritis Cartilage. 2010 Apr;18(4):476-99 PubMed

Eur J Gastroenterol Hepatol. 2011 Oct;23(10):876-80 PubMed

Lancet. 2013 Aug 31;382(9894):769-79 PubMed

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1844-55 PubMed

Semin Arthritis Rheum. 2014 Dec;44(3):253-63 PubMed

Ann Rheum Dis. 2016 Mar;75(3):552-9 PubMed

Molecules. 2015 Mar 06;20(3):4277-89 PubMed

Eur J Intern Med. 2015 May;26(4):285-91 PubMed

Br J Clin Pharmacol. 2015 Sep;80(3):599-606 PubMed

Stroke. 2016 Feb;47(2):356-64 PubMed

Curr Med Res Opin. 2016 Jun;32(6):997-1004 PubMed

N Engl J Med. 2016 Dec 29;375(26):2519-29 PubMed

J Clin Pharm Ther. 2017 Feb;42(1):27-38 PubMed

BMJ. 2017 May 9;357:j1909 PubMed

Ann Rheum Dis. 2017 Sep;76(9):1537-1543 PubMed

Ann Rheum Dis. 2017 Nov;76(11):1862-1869 PubMed

Semin Arthritis Rheum. 2017 Oct;47(2):e10 PubMed

Ann Rheum Dis. 2018 Jul;77(7):e39 PubMed

Aging Clin Exp Res. 2018 Feb;30(2):111-117 PubMed

JAMA. 2019 Mar 12;321(10):969-982 PubMed

Drugs Aging. 2019 Apr;36(Suppl 1):25-44 PubMed

Drugs Aging. 2019 Apr;36(Suppl 1):45-64 PubMed

Drugs Aging. 2019 Apr;36(Suppl 1):65-99 PubMed

Semin Arthritis Rheum. 2019 Apr 30;:null PubMed